

Drug Utilization Review Board
Meeting Minutes, Open Session
September 10, 2008

<p>Drug Utilization Review Board Meeting Minutes, Open Session EDS / White Lakes Mall Wichita / Kansas City Room Topeka, KS September 10, 2008</p>	<p>Members Present: Michael Burke, M.D.Ph.D., Chair Brenda Schewe, M.D. Roger Unruh, D.O. Judy McDaniel-Dowd, PA-C Dennis Grauer Ph.D. KHPA Staff Present: Margaret Smith, M.D. LeAnn Bell, Pharm.D. Shelly Liby EDS Staff Present: Deb Quintanilla, R.N. Lisa Todd, R.Ph. Karen Kluczykowski, R.Ph. Nancy Perry, R.N. ACS Staff: Jerry Bowmer, R.Ph.</p>	<p>Representatives: Charles Dahm, Amgen Scott Sabrswa, Amgen Dave Walters, Centocor Ortho Biotech Jim Baumann, Pfizer Kate Kwlesner, Wyeth Matthew Stafford, Merck</p>
TOPIC	DISCUSSION	DECISION AND/OR ACTION
<p>I. Call to Order</p>	<p>Dr. Michael Burke, Chair called the meeting to order at 10:05 a.m.</p>	
<p>II. Announcements</p>	<p>Dr. Margaret Smith introduced LeAnn Bell, Pharm.D., as the new Pharmacy Program Manager and Shelly Liby as the new Assistant Pharmacy Program Manager.</p> <p>She also announced that Tom Wilcox has resigned his position on the Board.</p>	
<p>III. Review and Approval of July 9, 2008 Minutes</p>	<p>Dr. Schewe pointed out that under New Business the list for tumor necrosis factor medication is missing number 1. Lisa Todd pointed out that it should be listed as 1-5 instead of 2-6.</p>	<p>Mrs. Dowd made a motion to approve the minutes with the corrections previously mentioned.</p> <p>Dr. Schewe seconded the motion and it carried</p>

	<p>On page 11, Dr. Schewe and Dr. Burke suggested that the first two sentences of the 2nd paragraph under Symlin and Byetta be deleted so that it is more readable and be more representative of the core issue.</p> <p>Dr. Schewe pointed out that on page 16 in the 2nd paragraph under Insomnia in the first sentence live should be changed to line.</p>	<p>by a unanimous vote.</p>
<p>IV. Old Business</p> <p>a Tumor Necrosis Factor Medications</p> <p>i. Update DMARD requirements on PA criteria</p>	<p>During the review of PA criteria at the last meeting it was unclear that there may have been some dynamic changes with regard to indication and age. Lisa Todd put together a table to summarize the current state of affairs with the tumor necrosis factor antagonists. Ms. Todd stated that currently all TNF medication PA criteria require a DMARD or failed therapy. Updates to some of the package inserts show that this is no longer the case for all of the TNF medications. For example Humira® can be used a single agent for adult rheumatoid arthritis. Where as Remicade® must be used in conjunction with a DMARD. Cimzia® still requires a DMARD or failed therapy.</p> <p>Dr. Dahm, medical liaison for Amgen, requested that the Enbrel® PA question on line five come in line to reflect the package guidelines. Dr. Burke stated that according to the updated information the change is appropriate.</p> <p>Dr. Burke commented about the FDA alert regarding the TNF antagonists and the risk of</p>	<p>Dr. Burke asked that for archival purposes Ms. Todd modify the table with the changes discussed.</p> <p>Dr. Burke asked for a motion to bring the corrected table back with recommendation for PA modifications consistent with the table.</p> <p>So moved by Dr. Schewe.</p> <p>Dr. Grauer seconded the motion and it carried by a unanimous vote.</p>

<p>c Uroxatral™ (Alfuzosin)</p> <p>i. Recommendation of removal of gender restrictions</p>	<p>constipation with advanced illness.</p> <ol style="list-style-type: none"> 3. Patient must be receiving palliative care. 4. Documentation of current opioid therapy. 5. Pretreatment documented inadequate laxative therapy. 6. Patient does not have known or suspected mechanical gastrointestinal obstruction. 7. Patient is not pregnant or breast feeding. <p>Prior Authorizations will be approved for 4 months per lifetime.</p> <p>Dr. Burke asked for public comment. There was none.</p> <p>The board discussed the PA criteria. Nancy Perry, an EDS nurse, expressed concern that Hospice palliative care is different from general palliative care, but combining bullets 2 and 3 would take care of that concern. It was decided that bullets 2 and 3 would be combined.</p> <p>Deb Quintanilla asked for more clarification on inadequate laxative therapy. In response to this Dr. Burke stated that bullet 5 should be changed to say “response to standard laxative therapy has not been sufficient.”</p> <p><u>Uroxatral™</u></p> <p>Ms. Todd stated that Uroxatral™ is a drug only</p>	<p>Dr. Burke asked for a motion to approve the PA criteria with the changes discussed.</p> <p>So moved by Dr. Grauer.</p> <p>Dr. Schewe seconded the motion and it carried by a unanimous vote.</p> <p>Dr. Burke stated that the board will review the utilization data in 6 months.</p>
--	--	--

	<p>approved for use in men. The Pharmacy Helpdesk phone has received feedback from Urologists stating that they would like to use this drug for women to help with incontinence. There is currently a gender restriction on this drug in the computer system. A pharmacy claim for Uroxatral™ for a female patient will deny.</p> <p>Dr. Smith stated that there are similar drugs being used in women that are all off label.</p> <p>Dr. Grauer asked if there were any studies in women with this drug. The board was not aware of any scientific studies.</p> <p>There was discussion about Flomax® and whether or not there is a hard edit for males; there is not. However, it is FDA approved only for males. It is believed that indicators received from FDB don't require gender restrictions on Flomax®; Karen Kluczykowski can verify.</p> <p>Dr. Burke stated we may permit off label use inadvertently, but our policies are not intended to promote off label use particularly without any scientific evidence of effectiveness.</p>	<p>Dr. Grauer made a motion to not remove gender restrictions.</p> <p>Dr. Schewe seconded the motion and it carried by a unanimous vote.</p>
<p>VI. Miscellaneous</p> <p>a. New location EDS, an HP company 6700 SW Topeka Blvd. Building 283 (2 North & J Street) Topeka, KS 66619</p>	<p>Ms. Todd announced that the next meeting is November 12, 2008 and will be held at the new location. She will provide directions.</p> <p>Dr. Burke asked if there was any other business. Dr. Smith reminded the Board that we are in need of a long term care and retail pharmacist to serve on the Board. Dr. Burke suggested a pharmacist, Dr. Meg Damon, who is working in</p>	

	the hospital environment. Dr. Smith said that she would look at the specific criteria.	
VII. Adjournment	Dr. Burke announced the meeting was adjourned.	Dr. Unruh made a motion to adjourn the meeting. Mrs. Dowd seconded and it was carried by a unanimous vote.